We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Marketing of Unapproved Biologics Top Concern for CBER, Says FDA Official
Marketing of Unapproved Biologics Top Concern for CBER, Says FDA Official
Companies selling unapproved biologics products is a major ongoing concern for the FDA’s CBER, says an agency consumer safety expert, speaking at the 2023 PDA/FDA Joint Regulatory Conference on Wednesday.